Li-Na Chou, Min-Li Chen
Influencing Factors of the Body Mass Index of Elementary Students in Southern Taiwan
International journal of environmental research and public health
semaglutide liraglutide glucagonlike peptide 1 receptor agonists glp1 ras approved us food drug administration patients type ii diabetes mellitus t2dm patients t2dm treated liraglutide michael e debakey veterans affairs medical center medvamc converted semaglutide primary objective assess changes glycemic control cost savings resulted conversion conducted retrospective chart review veterans without retinopathy treated medvamc march 1 2021 november 30 2021 converted liraglutide 06 mg 12 mg daily semaglutide 025 mg weekly titrated 05 mg weekly 4 weeks compared hemoglobin a1c hba1c values baseline 3 12 months following conversion assess glycemic control cost savings evaluated using outpatient pharmacy data study 411 patients converted liraglutide semaglutide 49 additional patients met criteria clinician education 14 converted result total 304 patients met criteria inclusion baseline patients mean sd levels included hba1c 81 15 blood glucose 1874 442 mgdl body weight 1129 230 kg three 12 months postconversion patients mean sd hba1c significantly decreased 76 14 p 001 blood glucose decreased 1726 390 mgdl p 001 body weight decreased 1052 323 kg p 001 cost savings exceeding 400000 resulted liraglutide semaglutide conversion conversion liraglutide semaglutide led significant hba1c decrease weight loss resulted minimal changes patients antihyperglycemic regimen common adverse effects included hypoglycemia gastrointestinal intolerance due low conversion rate liraglutide semaglutide following education effective method education clinicians promote teleretinal imaging conversion warranted lastly although semaglutide cost savings initiative medvamc resulted significant savings institution full costeffective analysis needed conclusion